Royalty Pharma plc Income (Loss) from Equity Method Investments
Royalty Pharma plc (RPRX) reported Income (Loss) from Equity Method Investments of $4.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2026-08-05
- Royalty Pharma plc income (loss) from equity method investments for the quarter ending 2026-06-30 was $4.08M, a 51.39% increase year-over-year.
- Royalty Pharma plc income (loss) from equity method investments for the quarter ending 2026-03-31 was $21.76M, a 237.70% increase year-over-year.
- Royalty Pharma plc income (loss) from equity method investments for the quarter ending 2025-12-31 was $4.00M, a 87.35% decline year-over-year.
- Royalty Pharma plc income (loss) from equity method investments for the quarter ending 2025-09-30 was $15.95M, a 53.24% increase year-over-year.
- Royalty Pharma plc income (loss) from equity method investments for fiscal 2025 was $29.09M, a 1.76% decline from fiscal 2024.
- Royalty Pharma plc income (loss) from equity method investments for fiscal 2024 was $29.61M, a 2.52% increase from fiscal 2023.
- Royalty Pharma plc income (loss) from equity method investments for fiscal 2023 was $28.88M.
- Royalty Pharma plc income (loss) from equity method investments for fiscal 2022 was -$8.97M.
| Period end | Income (Loss) from Equity Method Investments 3 month | Income (Loss) from Equity Method Investments 6 month | Income (Loss) from Equity Method Investments 9 month | Income (Loss) from Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.08M 10-Q · filed 2026-08-05 | $25.84M 10-Q · filed 2026-08-05 | $29.84M derived: sum of 3 quarters · filed 2026-08-05 | $45.79M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $21.76M 10-Q · filed 2026-05-06 | $25.76M derived: sum of 2 quarters · filed 2026-05-06 | $41.71M derived: sum of 3 quarters · filed 2026-05-06 | $44.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $19.95M derived: sum of 2 quarters · filed 2026-02-11 | $22.65M derived: sum of 3 quarters · filed 2026-08-05 | $29.09M 10-K · filed 2026-02-11 |
| 2025-09-30 | $15.95M 10-Q · filed 2025-11-05 | $18.64M derived: sum of 2 quarters · filed 2026-08-05 | $25.08M 10-Q · filed 2025-11-05 | $56.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.69M 10-Q · filed 2026-08-05 | $9.14M 10-Q · filed 2026-08-05 | $40.79M derived: sum of 3 quarters · filed 2026-08-05 | $51.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.44M 10-Q · filed 2026-05-06 | $38.09M derived: sum of 2 quarters · filed 2026-05-06 | $48.50M derived: sum of 3 quarters · filed 2026-05-06 | $50.20M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $31.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $42.06M derived: sum of 2 quarters · filed 2026-02-11 | $43.76M derived: sum of 3 quarters · filed 2026-02-11 | $29.61M 10-K · filed 2026-02-11 |
| 2024-09-30 | $10.41M 10-Q · filed 2025-11-05 | $12.11M derived: sum of 2 quarters · filed 2025-11-05 | -$2.04M 10-Q · filed 2025-11-05 | -$1.77M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $1.70M 10-Q · filed 2025-08-06 | -$12.45M 10-Q · filed 2025-08-06 | -$12.18M derived: sum of 3 quarters · filed 2026-02-11 | -$17.40M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$14.15M 10-Q · filed 2025-05-08 | -$13.88M derived: sum of 2 quarters · filed 2026-02-11 | -$19.10M derived: sum of 3 quarters · filed 2026-02-11 | -$19.87M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | -$4.95M derived: sum of 2 quarters · filed 2026-02-11 | -$5.72M derived: sum of 3 quarters · filed 2026-02-11 | $28.88M 10-K · filed 2026-02-11 |
| 2023-09-30 | -$5.22M 10-Q · filed 2024-11-06 | -$5.99M derived: sum of 2 quarters · filed 2024-11-06 | $28.61M 10-Q · filed 2024-11-06 | $21.76M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | -$770.00K 10-Q · filed 2024-08-08 | $33.84M 10-Q · filed 2024-08-08 | $26.98M derived: sum of 3 quarters · filed 2025-02-12 | $23.73M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $34.61M 10-Q · filed 2024-05-09 | $27.75M derived: sum of 2 quarters · filed 2025-02-12 | $24.50M derived: sum of 3 quarters · filed 2025-02-12 | $25.24M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$10.11M derived: sum of 2 quarters · filed 2025-02-12 | -$9.37M derived: sum of 3 quarters · filed 2025-02-12 | -$8.97M 10-K · filed 2025-02-12 |
| 2022-09-30 | -$3.25M 10-Q · filed 2023-11-08 | -$2.51M derived: sum of 2 quarters · filed 2023-11-08 | -$2.12M 10-Q · filed 2023-11-08 | -$40.14M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $737.00K 10-Q · filed 2023-08-08 | $1.13M 10-Q · filed 2023-08-08 | -$36.89M derived: sum of 3 quarters · filed 2024-02-15 | -$34.14M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $397.00K 10-Q · filed 2023-05-09 | -$37.63M derived: sum of 2 quarters · filed 2024-02-15 | -$34.88M derived: sum of 3 quarters · filed 2024-02-15 | -$17.18M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$38.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$35.27M derived: sum of 2 quarters · filed 2024-02-15 | -$17.57M derived: sum of 3 quarters · filed 2024-02-15 | -$19.49M 10-K · filed 2024-02-15 |
| 2021-09-30 | $2.75M 10-Q · filed 2022-11-08 | $20.45M derived: sum of 2 quarters · filed 2022-11-08 | $18.53M 10-Q · filed 2022-11-08 | $29.03M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $17.70M 10-Q · filed 2022-08-04 | $15.78M 10-Q · filed 2022-08-04 | $26.28M derived: sum of 3 quarters · filed 2023-02-15 | $40.02M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$1.92M 10-Q · filed 2022-05-05 | $8.58M derived: sum of 2 quarters · filed 2023-02-15 | $22.32M derived: sum of 3 quarters · filed 2023-02-15 | $51.62M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $24.24M derived: sum of 2 quarters · filed 2023-02-15 | $53.53M derived: sum of 3 quarters · filed 2023-02-15 | $44.46M 10-K · filed 2023-02-15 |
| 2020-09-30 | $13.74M 10-Q · filed 2021-11-10 | $43.03M derived: sum of 2 quarters · filed 2021-11-10 | $33.96M 10-Q · filed 2021-11-10 | $23.16M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $29.29M 10-Q · filed 2021-08-11 | $20.22M 10-Q · filed 2021-08-11 | $9.42M derived: sum of 3 quarters · filed 2022-02-15 | $1.37M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$9.07M 10-Q · filed 2021-05-11 | -$19.88M derived: sum of 2 quarters · filed 2022-02-15 | -$27.92M derived: sum of 3 quarters · filed 2022-02-15 | -$36.06M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | -$10.80M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | -$18.84M derived: sum of 2 quarters · filed 2022-02-15 | -$26.99M derived: sum of 3 quarters · filed 2022-02-15 | -$32.52M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$8.04M 10-Q · filed 2020-11-12 | -$16.19M derived: sum of 2 quarters · filed 2020-11-12 | -$21.71M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$8.14M 10-Q · filed 2020-08-12 | -$13.67M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | -$7.02M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |